Skip to content


Sep 2022

Our technology on using cfDNA methylome to detect cancer has been published in Nature Communications!
News link: [UCLA News] [GenomeWeb] [HemOnc Today] [ScieneDaily] [Biocompare]

Sep 2022

EarlyDx has been awarded a NIH SBIR Phase II grant on validating our cfDNA methylome technology for the early detection of liver and lung cancer.

May 2022

EarlyDx announced the appointment of Guanghui Hu as co-CEO.

Sep 2021

EarlyDx Awarded an NIH SBIR Phase I Contract on the Further Development of the Cloud Computing Platform for Liquid Biopsy.

April 2021

Co-founder Jasmine Zhou presented EarlyDx’s CancerRadar Technology and Clinical Data in Oral Presentation at AACR Annual Meeting 2021 on April 10, 2021.

May 2020

EarlyDx Awarded an NIH SBIR Phase I Grant for Assay Development.

Feb 2020

EarlyDx closed $5M Series Seed-1 Fundraising Led by Alpha Edison.

May 2019

EarlyDx Exhibits its One-Stop Shop Bioinformatics Platform, EarlyDx-Cloud, at 2019 ASCO Annual Meeting.